522 related articles for article (PubMed ID: 33741405)
61. The effects of delta 9-tetrahydrocannabinol alone and in combination with cannabidiol on fixed-interval performance in rhesus monkeys.
Brady KT; Balster RL
Psychopharmacology (Berl); 1980; 72(1):21-6. PubMed ID: 6258188
[TBL] [Abstract][Full Text] [Related]
62. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.
Booker L; Naidu PS; Razdan RK; Mahadevan A; Lichtman AH
Drug Alcohol Depend; 2009 Nov; 105(1-2):42-7. PubMed ID: 19679411
[TBL] [Abstract][Full Text] [Related]
63. Individual and combined effects of cannabidiol and Δ
Wall MB; Freeman TP; Hindocha C; Demetriou L; Ertl N; Freeman AM; Jones AP; Lawn W; Pope R; Mokrysz C; Solomons D; Statton B; Walker HR; Yamamori Y; Yang Z; Yim JL; Nutt DJ; Howes OD; Curran HV; Bloomfield MA
J Psychopharmacol; 2022 Jun; 36(6):732-744. PubMed ID: 35596578
[TBL] [Abstract][Full Text] [Related]
64. Neural correlates of interactions between cannabidiol and Δ(9) -tetrahydrocannabinol in mice: implications for medical cannabis.
Todd SM; Arnold JC
Br J Pharmacol; 2016 Jan; 173(1):53-65. PubMed ID: 26377899
[TBL] [Abstract][Full Text] [Related]
65. Cannabidiol-Δ
Britch SC; Wiley JL; Yu Z; Clowers BH; Craft RM
Drug Alcohol Depend; 2017 Jun; 175():187-197. PubMed ID: 28445853
[TBL] [Abstract][Full Text] [Related]
66. Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats.
Malone DT; Jongejan D; Taylor DA
Pharmacol Biochem Behav; 2009 Aug; 93(2):91-6. PubMed ID: 19393686
[TBL] [Abstract][Full Text] [Related]
67. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
68. Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination.
Zuardi AW; Karniol IG
Braz J Med Biol Res; 1983 Jul; 16(2):141-6. PubMed ID: 6317104
[TBL] [Abstract][Full Text] [Related]
69. Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101.
Stollenwerk TM; Pollock S; Hillard CJ
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500787
[TBL] [Abstract][Full Text] [Related]
70. Effects of cannabidiol in cannabis flower: Implications for harm reduction.
Gibson LP; Karoly HC; Ellingson JM; Klawitter J; Sempio C; Squeri JE; Bryan AD; Bidwell LC; Hutchison KE
Addict Biol; 2022 Jan; 27(1):e13092. PubMed ID: 34467598
[TBL] [Abstract][Full Text] [Related]
71. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.
Roser P; Juckel G; Rentzsch J; Nadulski T; Gallinat J; Stadelmann AM
Eur Neuropsychopharmacol; 2008 Aug; 18(8):569-77. PubMed ID: 18544469
[TBL] [Abstract][Full Text] [Related]
72. Effect of combined doses of Δ
Rock EM; Sullivan MT; Pravato S; Pratt M; Limebeer CL; Parker LA
Psychopharmacology (Berl); 2020 Mar; 237(3):901-914. PubMed ID: 31897571
[TBL] [Abstract][Full Text] [Related]
73. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities.
Xu DH; Cullen BD; Tang M; Fang Y
Curr Pharm Biotechnol; 2020; 21(5):390-402. PubMed ID: 31793418
[TBL] [Abstract][Full Text] [Related]
74. The effects of cannabidiol and Δ9-tetrahydrocannabinol, alone and in combination, in the maximal electroshock seizure model.
Dlugosz L; Zhou HZ; Scott BW; Burnham M
Epilepsy Res; 2023 Feb; 190():107087. PubMed ID: 36646020
[TBL] [Abstract][Full Text] [Related]
75. Drug-drug interactions as a result of co-administering Δ
Rong C; Carmona NE; Lee YL; Ragguett RM; Pan Z; Rosenblat JD; Subramaniapillai M; Shekotikhina M; Almatham F; Alageel A; Mansur R; Ho RC; McIntyre RS
Expert Opin Drug Saf; 2018 Jan; 17(1):51-54. PubMed ID: 29082802
[TBL] [Abstract][Full Text] [Related]
76. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
[TBL] [Abstract][Full Text] [Related]
77. A Model of Δ
Spencer S; Neuhofer D; Chioma VC; Garcia-Keller C; Schwartz DJ; Allen N; Scofield MD; Ortiz-Ithier T; Kalivas PW
Biol Psychiatry; 2018 Oct; 84(8):601-610. PubMed ID: 29861097
[TBL] [Abstract][Full Text] [Related]
78. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
[TBL] [Abstract][Full Text] [Related]
79. The therapeutic use of cannabinoids: Forensic aspects.
Indorato F; Liberto A; Ledda C; Romano G; Barbera N
Forensic Sci Int; 2016 Aug; 265():200-3. PubMed ID: 27038587
[TBL] [Abstract][Full Text] [Related]
80. Are oral cannabinoids safe and effective in refractory neuropathic pain?
Attal N; Brasseur L; Guirimand D; Clermond-Gnamien S; Atlami S; Bouhassira D
Eur J Pain; 2004 Apr; 8(2):173-7. PubMed ID: 14987627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
